Search

Your search keyword '"Ram-Wolff C"' showing total 496 results
Start Over Author "Ram-Wolff C"
496 results on '"Ram-Wolff C"'

5. Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies

Author

Campbell, BA, Dobos, G, Haider, Z, Bagot, M, Evison, F, van Der Weyden, C, Mccormack, C, Ram-Wolff, C, Miladi, M, Prince, HM, Scarisbrick, JJ, Campbell, BA, Dobos, G, Haider, Z, Bagot, M, Evison, F, van Der Weyden, C, Mccormack, C, Ram-Wolff, C, Miladi, M, Prince, HM, and Scarisbrick, JJ

Abstract

Traditionally, Sezary syndrome (SS) has been associated with few therapeutic options and poor prognosis, with 5-year disease-specific survival (DSS) less than one-third in historical cohorts. However, newer therapies and combinations are associated with impressive time-to-next-treatment (TTNT), particularly allogeneic stem-cell transplantation (AlloSCT) and combination therapies notably those including extracorporeal photopheresis. In this multicentre, international study, we explored the prognostic outcomes of 178 patients exclusively managed for SS, diagnosed between 2012 and 2020, and treated in the modern therapeutic era. In this cohort, 58 different therapies were delivered, with 13.5% of patients receiving AlloSCT. Long-term survival exceeded historical reports with 5-year DSS and OS of 56.4% and 53.4% respectively. In those receiving AlloSCT, prognosis was excellent: 5-year DSS and OS were 90.5% and 78.0% respectively. Confirming the results from the Cutaneous Lymphoma International Consortium (CLIC), LDH and LCT had significant prognostic impact. Unlike earlier studies, stage did not have prognostic impact; we speculate that greater relative benefit favours patients with extensive lymphomatous nodal disease (Stage IVA2) compared to historical reports. For patients ineligible for AlloSCT, the prognosis remains relatively poor (5-year DSS 51.4% and OS 49.6%), representing ongoing unmet needs for more effective novel agents and investigation of improved therapeutic combinations.

Published
2024

9. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Author

Quaglino, P., Maule, M., Prince, H.M., Porcu, P., Horwitz, S., Duvic, M., Talpur, R., Vermeer, M., Bagot, M., Guitart, J., Papadavid, E., Sanches, J.A., Hodak, E., Sugaya, M., Berti, E., Ortiz-Romero, P., Pimpinelli, N., Servitje, O., Pileri, A., Zinzani, P.L., Estrach, T., Knobler, R., Stadler, R., Fierro, M.T., Alberti Violetti, S., Amitay-Laish, I., Antoniou, C., Astrua, C., Chaganti, S., Child, F., Combalia, A., Fabbro, S., Fava, P., Grandi, V., Jonak, C., Martinez-Escala, E., Kheterpal, M., Kim, E.J., McCormack, C., Miyagaki, T., Miyashiro, D., Morris, S., Muniesa, C., Nikolaou, V., Ognibene, G., Onida, F., Osella-Abate, S., Porkert, S., Postigo-Llorente, C., Ram-Wolff, C., Ribero, S., Rogers, K., Sanlorenzo, M., Stranzenbach, R., Spaccarelli, N., Stevens, A., Zugna, D., Rook, A.H., Geskin, L.J., Willemze, R., Whittaker, S., Hoppe, R., Scarisbrick, J., and Kim, Y.

Published
2017
Full Text
View/download PDF

11. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study

Author

Beylot‐Barry, M., primary, Quereux, G., additional, Nardin, C., additional, Duval‐Modeste, A.‐B., additional, Dereure, O., additional, Dalac‐Rat, S., additional, Dobos, G., additional, Pham‐Ledard, A., additional, Ram‐Wolff, C., additional, D'Incan, M., additional, Grange, F., additional, Braniste, V., additional, and Bagot, M., additional

Published
2023
Full Text
View/download PDF

12. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Author

Campbell, BA, Dobos, G, Haider, Z, Prince, HM, Bagot, M, Evison, F, van der Weyden, C, Mccormack, C, Ram-Wolff, C, Miladi, M, Scarisbrick, JJ, Campbell, BA, Dobos, G, Haider, Z, Prince, HM, Bagot, M, Evison, F, van der Weyden, C, Mccormack, C, Ram-Wolff, C, Miladi, M, and Scarisbrick, JJ

Abstract

Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9 months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies) and classified into 17 treatment groups. The most common first-line treatments were extracorporeal photopheresis (ECP)-containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4 months). First-line, combination therapies had longer median TTNT than monotherapies, 10.0 vs 5.0 months (P = .004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2 months for mid-line (2nd-4th line) and late-line (≥5th line), respectively (P < .001). First-line ECP-containing treatments were associated with longer median TTNT than non-ECP-containing treatments, 9.0 vs 4.9 months (P = .007). For both ECP-monotherapy and ECP-containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for SS and favor early inclusion of ECP in the treatment algorithm for those who can access it.

Published
2023

13. Dermatomyositis versus mycosis fungoides: Challenges in the diagnosis of erythroderma with associated myositis

Author

Masson, A. de, primary, Ram-Wolff, C., additional, Bouaziz, J.D., additional, Cayuela, J.M., additional, Lorillon, G., additional, Frumholtz, L., additional, Cassius, C., additional, Petit, A., additional, Léonard-Louis, S., additional, Battistella, M., additional, Vignon-Pennamen, M.D., additional, Rivet, J., additional, Meignin, V., additional, Duverger, L., additional, Jachiet, M., additional, Bagot, M., additional, and Lazaridou, I., additional

Published
2023
Full Text
View/download PDF

14. Neutrophilic dermatoses

Author

Delaleu, J., primary, Lepelletier, C., additional, Calugareanu, A., additional, De Masson, A., additional, Charvet, E., additional, Petit, A., additional, Giurgea, I., additional, Amselem, S., additional, Karabina, S., additional, Jachiet, M., additional, Mahevas, T., additional, Ram-Wolff, C., additional, Vignon-Pennamen, M.-D., additional, Bagot, M., additional, Battistella, M., additional, and Bouaziz, J.-D., additional

Published
2022
Full Text
View/download PDF

15. Survie globale et prise en charge du syndrome de Sézary : étude rétrospective multicentrique de 402 cas

Author

Bozonnat, A., primary, Beylot-Barry, M., additional, Dereure, O., additional, D’Incan, M., additional, Quéreux, G., additional, Guenova, E., additional, Grange, F., additional, Viguier, M., additional, Ram-Wolff, C., additional, Boulinguez, S., additional, Troin, L., additional, Montaudié, H., additional, Feldmeyer, L., additional, Beltraminelli, H., additional, Bonnet, N., additional, Maubec, E., additional, Franck, N., additional, Machet, L., additional, Chasset, F., additional, Saiag, P., additional, Hainault, E., additional, Brunet Possenti, F., additional, Michel, C., additional, Bens, G., additional, Adamski, H., additional, Aubin, F., additional, Faiz, S., additional, Mortier, L., additional, Joly, P., additional, Tedbirt, B., additional, Templier, I., additional, Bouaziz, J.D., additional, Battistella, M., additional, Oro, S., additional, Bagot, M., additional, Serret-Larmande, A., additional, Montlahuc, C., additional, and de Masson, A., additional

Published
2022
Full Text
View/download PDF

17. CCR8 : nouvelle cible thérapeutique dans les lymphomes T cutanés

Author

de Masson, A., primary, Giustiniani, J., additional, Dobos, G., additional, Moins-Teisserenc, H., additional, Battistella, M., additional, Ortonne, N., additional, Ram-Wolff, C., additional, Bouaziz, J.D., additional, Mourah, S., additional, Marie-Cardine, A., additional, Bagot, M., additional, Kupper, T., additional, Clark, R., additional, and Bensussan, A., additional

Published
2022
Full Text
View/download PDF

19. Les anticorps monoclonaux chimériques anti-ICOS 314.8 inhibent les cellules tumorales et les lymphocytes T régulateurs dans le syndrome de Sézary

Author

Amatore, F., primary, Barré, M., additional, Orlanducci, F., additional, Lopez, M., additional, Castellano, R., additional, Ram-Wolff, C., additional, Gorvel, L., additional, Goubard, A., additional, Gaudy-Marqueste, C., additional, Bagot, M., additional, Bensussan, A., additional, Delaporte, E., additional, and Olive, D., additional

Published
2022
Full Text
View/download PDF

20. Lymphomes B cutanés primitifs centro-folliculaires à évolution systémique

Author

Li, A., primary, Rivet, J., additional, Vignon-Pennamen, M.D., additional, Lehmann-Che, J., additional, Mourah, S., additional, Cayuela, J.M., additional, Lepelletier, C., additional, Ram-Wolff, C., additional, Bouaziz, J.D., additional, Picard, A., additional, Troin, L., additional, Cardot-Leccia, N., additional, Bagot, M., additional, De Masson, A., additional, and Battistella, M., additional

Published
2022
Full Text
View/download PDF

21. Revue systématique de la littérature des cas de mycosis fongoïde chalazodermique et de ses options thérapeutiques

Author

Battesti, G., primary, Ram-Wolff, C., additional, Dobos, G., additional, Guenova, E., additional, Bouaziz, J.D., additional, Mourah, S., additional, Cayuela, J.M., additional, Moins-Teisserenc, H., additional, Battistella, M., additional, Vignon-Pennamen, M.D., additional, Rivet, J., additional, Bagot, M., additional, and De Masson, A., additional

Published
2022
Full Text
View/download PDF

24. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas

Author

de Masson, A, primary, Bensussan, A, additional, Dobos, G, additional, Moins-Teisserenc, H, additional, Eustaquio, T, additional, Battistella, M, additional, Ortonne, N, additional, Ram-Wolff, C, additional, Bouaziz, JD, additional, Marie-Cardine, A, additional, Mourah, S, additional, Bagot, M, additional, Kupper, TS, additional, Clark, RA, additional, and Giustiniani, J, additional

Published
2022
Full Text
View/download PDF

25. Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome

Author

Amatore, FA, primary, Barre, M, additional, Orlanducci, F, additional, Lopez, M, additional, Castellano, R, additional, Ram-Wolff, C, additional, Gorvel, L, additional, Goubard, A, additional, Gaudy-Marqueste, C, additional, Bagot, M, additional, Bensussan, A, additional, Delaporte, E, additional, and Olive, D, additional

Published
2022
Full Text
View/download PDF

26. Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study

Author

Mitsunaga, K, primary, Bagot, M, additional, Beylot-Barry, M, additional, Ram-Wolff, C, additional, Guenova, E, additional, Fassnacht, C, additional, Hodak, E, additional, Amitay, I, additional, Papadavid, E, additional, Jonak, C, additional, Porkert, S, additional, Scarisbrick, J, additional, Applewaite, R, additional, Nicolay, J, additional, Quaglino, P, additional, Sanches Jr, J, additional, Martins, J Cury, additional, and Ortiz-Romero, PL, additional

Published
2022
Full Text
View/download PDF

30. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas

Author

D'Incan, M, Ingen-Housz-Oro, S, Beylot-Barry, M, Joly, P., Grange, F., Quereux, G., Templier, I., Ram-Wolff, C, Adamski, H., Lambert, C., Descours, C., D’Incan, M., Ingen‐Housz‐Oro, S., Beylot‐Barry, M., Ram‐Wolff, C., CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
medicine.medical_specialty, Skin Neoplasms, integumentary system, business.industry, [SDV]Life Sciences [q-bio], Dermatology, Prognosis, Lymphoma, T-Cell, Cutaneous, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Lymphomatoid Papulosis, medicine, Overall survival, Humans, Lymphoma, Large-Cell, Anaplastic, Radiology, Skin lesion, NODAL, business, ComputingMilieux_MISCELLANEOUS
Abstract

primary cutaneous anaplastic lymphomas (pcALCL) commonly present as solitary or grouped skin lesions and have a 5-year specific survival greater than 91% (1-3). One study showed that, in cases of extracutaneous extension, 5-year overall survival is 41% (4). At diagnosis some patients have skin and locoregional node involvement but their prognosis is as favorable as that of patients with lesions limited to the skin (1).

Published
2020

31. Cutaneous gamma delta T‐Cell lymphoma with indolent evolution: a series of five cases

Author

Galadari, A., primary, Ram‐Wolff, C., additional, Al Hage, J., additional, Battistella, M., additional, Vignon‐Pennamen, M.D., additional, Rivet, J., additional, Cayuela, J.M., additional, Gabison, G., additional, Moins‐Teisserenc, H., additional, Mourah, S., additional, Ingen‐Housz‐Oro, S., additional, Le Corre, Y., additional, Bagot, M., additional, and de Masson, A., additional

Published
2022
Full Text
View/download PDF

35. Quatre cas de mycosis fongoïde pédiatrique révélés par une kératodermie palmoplantaire psoriasiforme récalcitrante

Author

Grandjacquot, S., Ram-Wolff, C., De Masson, A., Battistela, M., Drabent, P., Fraitag, S., Bataille, P., Montaï, Q. Murat de, and Bourrat, E.

Abstract

Le psoriasis est une cause très fréquente de kératodermie palmoplantaire (KPP) inflammatoire acquise, quelle que soit la tranche d’âge. À l’inverse, cette dernière est très rarement l’expression d’un lymphome T épidermotrope. Chez l’adulte, une KPP est dans 0,6 % des cas une manifestation d’un lymphome T cutané, principalement des mycosis fongoïdes (MF) érythrodermiques ou des syndromes de Sézary. Nous rapportons 4 cas pédiatriques de KPP inflammatoires traitées comme des KPP psoriasiques, puis diagnostiquées MF après échec de plusieurs lignes de traitement systémique.

Published
2024
Full Text
View/download PDF

36. Étude « Moga-Stop » : évolution des patients atteints de syndrome de Sézary traités par mogamulizumab après arrêt du traitement (hors progression)

Author

Tzoumpa, S., Oro, S., De Masson, A., Pham-Ledard, A., El Aarbaoui, T., Dereure, O., Quéreux, G., Faiz, S., De Vicq De Cumptich, M., Ram-Wolff, C., Janela-Lapert, R., Guenova, E., Lheure, C., Le Core, Y., Adamski, H., Blanchard, M., Bonnet, N., Amatore, F., Grange, F., Troin, L., Bagot, M., and Beylot-Barry, M.

Abstract

Le mogamulizumab (moga), anticorps monoclonal anti-CCR4, a montré une augmentation de la survie sans progression (SSP) dans le mycosis fongoïde (MF) et le syndrome de Sézary (SS) où il est approuvé en 2e ligne. Des rémissions de longue durée ont été décrites, mais les données sur les stratégies d’arrêt et l’évolution après arrêt manquent. Nous avons conduit une étude pour évaluer l’évolution des patients atteints de SS ayant arrêté le moga pour tout autre motif qu’une progression de la maladie.

Published
2024
Full Text
View/download PDF

39. Incidence et caractéristiques des carcinomes épidermoïdes cutanés chez les patients suivis et traités pour un syndrome de Sézary : étude nationale multicentrique

Author

Guillon, L., Ram-Wolff, C., Boulinguez, S., Beylot-Barry, M., D’incan, M., Adamski, H., Faiz, S., Le Corre, Y., Dalle, S., Amatore, F., Cornillault, A., Chaby, G., Duval-Modeste, A.B., Dalac, S., Oro, S., Montaudié, H., Nardin, C., Lenormand, C., Maubec, E., Stoebner, P.E., and Dereure, O.

Published
2023
Full Text
View/download PDF

40. Allogreffe dans les lymphomes T cutanés avancés (CUTALLO) : une étude prospective contrôlée multicentrique, appariée par score de propension

Author

De Masson, A., Beylot-Barry, M., Ram-Wolff, C., Méar, J.B., Dalle, S., D’incan, M., Oro, S., Orvain, C., Abraham, J., Dereure, O., Charbonnier, A., Cornillon, J., Longvert, C., Barete, S., Boulinguez, S., Wierzbicka-Hainaut, E., Aubin, F., Rubio, M.T., Bernard, M., Schmidt-Tanguy, A., Houot, R., Pham-Ledard, A., Michonneau, D., Brice, P., Labussière-Wallet, H., Bouaziz, J.D., Grange, F., Moins-Teisserenc, H., Jondeau, K., Michel, L., Mourah, S., Battistella, M., Daguindau, E., Loschi, M., Picard, A., Franck, N., Maillard, N., Huynh, A., Nguyen, S., Marcais, A., Chaby, G., Ceballos, P., Le Corre, Y., Maury, S., Bay, J.O., Adamski, H., Bachy, E., Forcade, E., Socié, G., Bagot, M., Chevret, S., and Peffault De Latour, R.

Published
2023
Full Text
View/download PDF

43. Traitement par lacutamab des malades ayant un lymphome T cutané au stade avancé : résultats d’efficacité dans l’étude TELLOMAK en fonction de la classification ganglionnaire actualisée

Author

Bagot, M., Kim, Y.H., Ortiz-Romero, P., Zinzani, P., Beylot-Barry, M., Dalle, S., Pham-Ledard, A., Jacobsen, E., Combalia, A., Huen, A., Mehta-Sha, N., Ram-Wolff, C., Khodadoust, M., Metha, A., Dereure, O., Battistella, M., Gru, A., Moins-Teisserenc, H., Viotti, J., Paiva, C., Boyer-Chammard, A., and Porcu, P.

Published
2023
Full Text
View/download PDF

46. Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group

Author

Hurabielle, C., Ingen-Housz-Oro, S., Ortonne, N., Cornillet-Lefèbvre, P., Merah, A., DʼIncan, M., Joly, P., Franck, N., Estève, E., Maubec, E., Grange, F., Machet, L., Laroche, L., Barete, S., Dalac, S., Mortier, L., Michel, C., Quereux, G., Saiag, P., Ram-Wolff, C., Lenormand, B., Wechsler, J., Bastuji-Garin, S., Bagot, M., and Delfau-Larue, M. H.

Published
2015
Full Text
View/download PDF

48. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group

Author

Bergqvist, C., primary, Beylot‐Barry, M., additional, Ram‐Wolff, C., additional, Vergier, B., additional, Bagot, M., additional, Battistella, M., additional, Dalle, S., additional, Balme, B., additional, Merlio, J. P., additional, Durupt, F., additional, Le Corre, Y., additional, Bonnet, N., additional, Le Bozec, P., additional, Skowron, F., additional, Vivard‐Wallee, I., additional, Dereure, O., additional, Brunet‐Possenti, F., additional, Ingen‐Housz‐Oro, S., additional, and Ortonne, N., additional

Published
2021
Full Text
View/download PDF

49. Diagnostic performance of high‐throughput sequencing of the T‐cell receptor beta gene for the diagnosis of cutaneous T‐cell lymphoma

Author

Zimmermann, C., primary, Boisson, M., additional, Ram‐Wolff, C., additional, Sadoux, A., additional, Louveau, B., additional, Vignon‐Pennamen, M.‐D., additional, Rivet, J., additional, Cayuela, J.‐M., additional, Dobos, G., additional, Moins‐Teisserenc, H., additional, Roelens, M., additional, Gruber, A., additional, Lebbé, C., additional, Bagot, M., additional, Battistella, M., additional, Mourah, S., additional, and Masson, A., additional

Published
2021
Full Text
View/download PDF

50. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P. Prince, H. M. Cowan, R. Vermeer, M. and Papadavid, E. Bagot, M. Servitjie, O. Berti, E. Guenova, E. Stadler, R. Querfeld, C. Busschots, A. M. Hodak, E. and Patsatsi, A. Sanches, J. Maule, M. Yoo, J. Kevin, M. and Fava, P. Ribero, S. Zocchi, L. Rubatto, M. Fierro, M. T. Wehkamp, U. Marshalko, M. Mitteldorf, C. Akilov, O. Ortiz-Romero, P. Estrach, T. Vakeva, L. Enz, P. A. and Wobser, M. Bayne, M. Jonak, C. Rubeta, M. Forbes, A. and Bates, A. Battistella, M. Amel-Kashipaz, R. Vydianath, B. Combalia, A. Georgiou, E. Hauben, E. Hong, E. K. and Jost, M. Knobler, R. Amitay-Laish, I. Miyashiro, D. and Cury-Martins, J. Martinez, X. Muniesa, C. Prag-Naveh, H. and Stratigos, A. Nikolaou, V. Quint, K. Ram-Wolff, C. and Rieger, K. Stranzenbach, R. Szepesi, A. Alberti-Violetti, S. and Felicity, E. Cerroni, L. Kempf, W. Whittaker, S. and Willemze, R. Kim, Y. Scarisbrick, J. J.

Abstract

Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results